AIM: Is it possible to reduce the frequency of neoadjuvant therapy for rectal carcinoma and nevertheless achieve a rate of more than 90% circumferential resection margin (CRM)-negative resection specimens by a novel concept of magnetic resonance imaging (MRI)-based therapy planning? MATERIALS AND METHODS: One hundred eighty-one patients from Berlin and Mainz, Germany, with primary rectal carcinoma, without distant metastasis, underwent radical surgery with curative intention. Surgical procedures applied were anterior resection with total mesorectal excision (TME) or partial mesorectal excision (PME; PME for tumours of the upper rectum) or abdominoperineal excision with TME. RESULTS: With MRI selection of the highest-risk cases, neoadjuvant therapy was given to only 62 of 181 (34.3%). The rate of CRM-negative resection specimens on histology was 170 of 181 (93.9%) for all patients, and in Berlin, only 1 of 93 (1%) specimens was CRM-positive. Patients selected for primary surgery had CRM-negative specimens on histology in 114 of 119 (95.8%). Those selected for neoadjuvant therapy had a lower rate of clear margin: 56 of 62 (90%). CONCLUSION: By applying a MRI-based indication, the frequency of neoadjuvant treatment with its acute and late adverse effects can be reduced to 30-35% without reduction of pathologically CRM-negative resection specimens and, thus, without the danger of worsening the oncological long-term results. This concept should be confirmed in prospective multicentre observation studies with quality assurance of MRI, surgery and pathology.
AIM: Is it possible to reduce the frequency of neoadjuvant therapy for rectal carcinoma and nevertheless achieve a rate of more than 90% circumferential resection margin (CRM)-negative resection specimens by a novel concept of magnetic resonance imaging (MRI)-based therapy planning? MATERIALS AND METHODS: One hundred eighty-one patients from Berlin and Mainz, Germany, with primary rectal carcinoma, without distant metastasis, underwent radical surgery with curative intention. Surgical procedures applied were anterior resection with total mesorectal excision (TME) or partial mesorectal excision (PME; PME for tumours of the upper rectum) or abdominoperineal excision with TME. RESULTS: With MRI selection of the highest-risk cases, neoadjuvant therapy was given to only 62 of 181 (34.3%). The rate of CRM-negative resection specimens on histology was 170 of 181 (93.9%) for all patients, and in Berlin, only 1 of 93 (1%) specimens was CRM-positive. Patients selected for primary surgery had CRM-negative specimens on histology in 114 of 119 (95.8%). Those selected for neoadjuvant therapy had a lower rate of clear margin: 56 of 62 (90%). CONCLUSION: By applying a MRI-based indication, the frequency of neoadjuvant treatment with its acute and late adverse effects can be reduced to 30-35% without reduction of pathologically CRM-negative resection specimens and, thus, without the danger of worsening the oncological long-term results. This concept should be confirmed in prospective multicentre observation studies with quality assurance of MRI, surgery and pathology.
Authors: J Strassburg; A Lewin; K Ludwig; L Kilian; J Linke; V Loy; P Knuth; O Püttcher; U Ruehl; F Stöckmann; M Hackenthal; W Hopfenmüller; A Huppertz Journal: Langenbecks Arch Surg Date: 2007-02-06 Impact factor: 3.445
Authors: David B Chessin; Warren Enker; Alfred M Cohen; Philip B Paty; Martin R Weiser; Leonard Saltz; Bruce D Minsky; W Douglas Wong; Jose G Guillem Journal: J Am Coll Surg Date: 2005-06 Impact factor: 6.113
Authors: Susanne Merkel; Daniela Klossek; Jonas Göhl; Thomas Papadopoulos; Werner Hohenberger; Paul Hermanek Journal: Int J Colorectal Dis Date: 2009-06-02 Impact factor: 2.571
Authors: Valerie Francescutti; Angela Coates; Lehana Thabane; Charles H Goldsmith; Mark N Levine; Marko Simunovic Journal: Can J Surg Date: 2013-12 Impact factor: 2.089